Wilson PD: Expression of aquaporin-1 and -2 during
nephrogenesis and in autosomal dominant polycystic kidney disease. Am J Physiol 271: F169 –F183, 1996
Mangoo-Karim R, Uchic M, Grant M, Shumate WA, Calvet
JP, Park CH, Grantham JJ: Renal epithelial fluid secretion
and cyst growth: The role of cyclic AMP. FASEB J 3:
2629 –2632, 1989
Belibi FA, Reif G, Wallace DP, Yamaguchi T, Olsen L, Li H,
Helmkamp GM Jr, Grantham JJ: Cyclic AMP promotes
growth and secretion in human polycystic kidney epithelial cells. Kidney Int 66: 964 –973, 2004
Gattone VH, Xiaofang W, Harris PC, Torres VE: Inhibition
of renal cystic disease development and progression by a
vasopressin V2 receptor antagonist. Nat Med 9: 1323–1326,
2003
Torres VE, Xiaofang W, Qian Q, Somlo S, Harris PC, Gattone VH: Effective treatment of an orthologous model of
autosomal dominant polycystic kidney disease. Nat Med
10: 363–364, 2004
Wang X, Gattone V 2nd, Harris PC, Torres VE: Effectiveness of vasopressin V2 receptor antagonists OPC-31260
and OPC-41061 on polycystic kidney disease development
in the PCK rat. J Am Soc Nephrol 16: 846 – 851, 2005
Torres VE: Vasopressin antagonists in polycystic kidney
disease. Kidney Int 68: 2405–2418, 2005
Christensen BM, Zelenina M, Aperia A, Nielsen S: Localization and regulation of PKA-phosphorylated AQP2 in
response to V2-receptor agonist/antagonist treatment.
Am J Physiol Renal Physiol 278: F29 –F42, 2000
Nielsen S, Frokiaer J, Marples D, Kwon TH, Agre P, Knepper MA: Aquaporins in the kidney: From molecules to
medicine. Physiol Rev 82: 205–244, 2002
Gabow PA, Kaehny WD, Johnson AM, Duley IT, MancoJohnson M, Lezotte DC, Schrier RW: The clinical utility of
renal concentrating capacity in polycystic kidney disease.
Kidney Int 35: 675– 680, 1989
Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Kornerup HJ, Posborg V: Expansion of extracellular volume in
early polycystic kidney disease. Acta Med Scand 219: 399 –
405, 1986
Bichet D: Polyuria and diabetes insipidus. In: The Kidney:
Physiology and Pathophysiology, edited by Seldin DW, Giebisch G, Philadelphia, Lippincott Williams & Wilkins, 2000,
pp 1261–1285
Muto S, Aiba A, Saito Y, Nakao K, Nakamura K, Tomita K,
Kitamura T, Kurabayashi M, Nagai R, Higashihara E, Harris PC, Katsuki M, Horie S: Pioglitazone improves the
phenotype and molecular defects of a targeted Pkd1 mu-tant. Hum Mol Genet 11: 1731–1742, 2002
Lu W, Peissel B, Babakhanlou H, Pavlova A, Geng L, Fan
X, Larson C, Brent G, Zhou J: Perinatal lethality with
kidney and pancreas defects in mice with a targetted Pkd1
mutation. Nat Genet 17: 179 –181, 1997
Kim K, Drummond K, Ibraghimov-Beskrovnaya O,
Klinger K, Arnaout MA: Polycystin 1 is required for the
structural integrity of blood vessels. Proc Natl Acad Sci
U S A 97: 1731–1736, 2000
Boulter C, Mulroy S, Webb S, Fleming S, Brindle K, Sandford R: Cardiovascular, skeletal, and renal defects in mice
with a targeted disruption of the Pkd1gene. Proc Natl Acad
Sci U S A 98: 12174 –12179, 2001
Lu W, Fan X, Basora N, Babakhanlou H, Law T, Rifai N,
